Articles

Probing cancer cells’ ‘ecosystem’

Pervasis Therapeutics, MIT sign patent license agreement to halt progression of cancer cells
Written byLori Lesko
| 4 min read

CAMBRIDGE, Mass.—Counting on changing the future of cancertherapy, Pervasis Therapeutics Inc. has entered into an exclusive patentlicense agreement with the Massachusetts Institute of Technology (MIT) aimed atdeveloping a breakthrough cell therapy targeted toward delivering a safer, moreeffective cancer treatment.

The key to Pervasis' interest lay in MIT's discovery thatendothelial cells may have a cancer-fighting role. If so, this could lead tothe discovery of a new drug to stop the advance of cancerous tumors—and evenprevent the cancer from returning, according to the two parties.

"The exclusive patent license agreement with MIT gives thecompany the rights to all discovery and development activities associated withcellular implants for cancer diagnosis, prognosis and treatment," says LynnBlenkhorn of Feinstein Kean Healthcare and spokesperson for Pervasis.

Dr. Elazer Edelman, professor of health sciences andtechnology at MIT, and MIT graduate student Joseph Franses, co-invented apatent portfolio directed to the use of cellular implants for cancer diagnosis,prognosis and treatment. Edelman is one of the original founders of Pervasisand a current member of the company's board of directors.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.